FDA Committee to Assess Compounded Peptides Due to Safety and Efficacy Concerns

The FDA's Pharmacy Compounding Advisory Committee is set to evaluate seven peptides, including BPC-157 and Semax, for their eligibility in compounding. This review is prompted by increasing public health concerns regarding the widespread promotion of these substances for various health claims, despite a lack of robust scientific evidence supporting their safety or effectiveness in humans.